Adverse cardiovascular effects of the coxibs

Journal of Medicinal Chemistry

Volumn 48, Issue 7, 2005, Pages 2251-2257

  Dogné, Jean Michel ^a   Supuran, Claudiu T ^b   Pratico, Domenico ^c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROSTACYCLIN; ROFECOXIB; VALDECOXIB;

ADENOMATOUS POLYP; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON CANCER; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; PAIN; SHORT SURVEY; SIDE EFFECT; SODIUM RETENTION; STROKE; SUDDEN DEATH; THROMBOEMBOLISM;

CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG AND NARCOTIC CONTROL; HUMANS; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK ASSESSMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 17144393290     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0402059     Document Type: Short Survey

References (26)

1. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000, 343, 1520-1528.
2. Juni, P.; Nartey, L.; Reichenbach, S.; Sterchi, R.; Dieppe, P. A.; et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004, 364, 2021-2029.
3. Topol, E. J.; Falk, G. W. A coxib a day won't keep the doctor away. Lancet 2004, 364, 639-640.
4. Fu, J. Y.; Masferrer, J. L.; Seibert, K.; Raz, A.; Needleman, P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 1990, 265, 16737-16740.
5. Chandrasekharan, N. V.; Dai, H.; Roos, K. L.; Evanson, N. K.; Tomsik, J.; et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13926-13931.
6. de Leval, X.; Hanson, J.; David, J. L.; Masereel, B.; Pirotte, B.; et al. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr. Med. Chem. 2004, 11, 1243-1252.
7. FitzGerald, G. A. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discovery 2003, 2, 879-890.
8. Taniura, S.; Kamitani, H.; Watanabe, T.; Eling, T. E. Transcriptional regulation of cyclooxygenase-1 by histone deacetylase inhibitors in normal human astrocyte cells. J. Biol. Chem. 2002, 277, 16823-16830.
9. Dogne, J. M.; de Leval, X.; Hanson, J.; Frederich, M.; Lambermont, B.; et al. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr. Med. Chem. 2004, 11, 1223-1241.
10. Belton, O.; Byrne, D.; Kearney, D.; Leahy, A.; Fitzgerald, D. J. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000, 102, 840-845.
11. McAdam, B. F.; Catella-Lawson, F.; Mardini, I. A.; Kapoor, S.; Lawson, J. A.; et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 272-277.
12. Dogne, J. M.; de Leval, X.; Benoit, P.; Delarge, J.; Masereel, B.; et al. Recent advances in antiplatelet agents. Curr. Med. Chem. 2002, 9, 577-589.
13. Pratico, D.; Cyrus, T.; Li, H.; FitzGerald, G. A. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 2000, 96, 3823-3826.
14. Cheng, Y.; Austin, S. C.; Rocca, B.; Koller, B. H.; Coffman, T. M.; et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002, 296, 539-541.
15. DeMaria, A. N.; Weir, M. R. Coxibs - beyond the GI tract: renal and cardiovascular issues. J. Pain Symptom Manage. 2003, 25, S41-S49.
16. Harris, R. C., Jr. Cyclooxygenase-2 inhibition and renal physiology. Am. J. Cardiol. 2002, 89, 10D-17D.
17. Julemont, F.; de Leval, X.; Michaux, C.; Damas, J.; Charlier, C.; et al. Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors. J. Med. Chem. 2002, 45, 5182-5185.
18. Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dube, D.; et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 2001, 296, 558-566.
19. Stichtenoth, D. O.; Frolich, J. C. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 2003, 63, 33-45.
20. Silverstein, F. E.; Faich, G.; Goldstein, J. L.; Simon, L. S.; Pincus, T.; et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA, J. Am. Med. Assoc. 2000, 284, 1247-1255.
21. Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. 2004, 47, 550-557.
22. Supuran, C. T.; Casini, A.; Mastrolorenzo, A.; Scozzafava, A. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini-Rev. Med. Chem. 2004, 4, 625-632.
23. Walter, M. F.; Jacob, R. F.; Day, C. A.; Dahlborg, R.; Weng, Y.; et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004, 177, 235-243.
24. Zhu, J.; Huang, J. W.; Tseng, P. H.; Yang, Y. T.; Fowble, J.; et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004, 64, 4309-4318.
25. Liu, X.; Yue, P.; Zhou, Z.; Khuri, F. R.; Sun, S. Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J. Natl. Cancer Inst. 2004, 96, 1769-1780.
26. Brune, K.; Hinz, B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand. J. Rheumatol. 2004, 33, 1-6.